Emerging Indian pharma multinationals: Latecomer catch-up strategies in a globalised high-tech industry

European Journal of International Management

Volumn 6, Issue 3, 2012, Pages 300-322

  Bruche, Gert ^a  

^a BERLIN SCHOOL OF ECONOMICS AND LAW   (Germany)

Author keywords

Big Pharma; Catch up strategies; Emerging multinationals; India; Indian multinational firms; Internationalisation strategies; Leapfrogging; Pharmaceutical industry; Triad multinationals

Indexed keywords

EID: 84861631653     PISSN: 17516757     EISSN: 17516765     Source Type: Journal    
DOI: 10.1504/EJIM.2012.047026     Document Type: Article

References (74)

1. Accenture (2007) The pursuit of high performance through research and development - understanding pharmaceutical research and development cost drivers. Available online at: http://www.accenture.com (accessed on 28 July 2010).
2. Accenture (2008) Multipolar world 2: the rise of the emerging country multinational. Available online at: http://www.accenture.com (accessed on 1 August 2010).
3. Amighini, A., Sanfilippo, M. and Rabelotti, R. (2009) 'The rise of multinationals from developing countries', WP Series - N. 04/09, Università del Piemonte Orientale, Vercelli, Italy.
4. Athreye, S. and Godley, A. (2009) 'Internationalization and technological leapfrogging in the pharmaceutical industry', Industrial and Corporate Change, Vol. 18, No. 2, pp.295-323.
5. Athreye, S., Kale, D. and Ramani, S.V. (2009) 'Experimentation with strategy and evolution of dynamic capability in the Indian pharmaceutical sector, Industrial and Corporate Change, Vol. 18, No. 4, pp.729-759.
6. Athreye, S. and Kapur, S. (2009) 'Introduction: The internationalization of Chinese and Indian firms - trends, motivations and strategy', Industrial and Corporate Change, Vol. 18, No. 2, pp.209-221.
7. Bang, N. (2009) A shot in the arm: Indian pharmaceutical sector has a bright future. Available online at: http://www.stockmarketsreview.com (accessed on 28 July 2010).
8. Bartlett, C.A. and Goshal, S. (2000) 'Going global - lessons from late movers', Harvard Business Review, Vol. 78, No. 2, pp.131-141.
9. BCG (2006) Harnessing the power of India - rising to the productivity challenge in biopharma R&D, The Boston Consulting Group. Available online at: http://www.bcg.com (accessed on 2 August 2010).
10. Bhalla, V. et al. (2006) Looking eastward - tapping India and China to reinvigorate the global biopharmaceutical industry, The Boston Consulting Group. Available online at: http://www.bcg.com (accessed on 2 August 2010).
11. Bhandari, M., Garg, R., Glassman, R., Ma, P.R. and Zemmel, R.W. (1999) 'A genetic revolution in health care', The McKinsey Quarterly, No. 4, pp.59-67.
12. Bruche, G. (2009) 'The emergence of China and India as new competitors in MNCs innovation networks', Competition & Change, Vol. 13, No. 3, pp.267-288.
13. BS (2010) 'Ranbaxy to shift focus from new drug research to generics', Business Standard, 16 May, New Delhi, India.
14. Budhwar, P.S., Varma, A., Katou,A. and Narayan, D. (2009) 'The role of HR in cross-border mergers and acquisitions: the case of Indian pharmaceutical firms', The Multinational Business Review, Vol. 17, No. 2, pp.89-110.
15. Cappelli. P., Singh, H., Singh, J. and Useem, M. (2010) The India Way: How India's Top Business Leaders Are Revolutionizing Management, Harvard Business Press Boston, MA.
16. CG (2010) Controller general of patents designs and trademarks: revised list of pharmaceutical product patents granted during 2005-06 to 200-10. Available online at: http://www.patentoffice.nic.in (accessed on 30 July 2010).
17. Chakravarthy, B. and Coughlan, S. (2009) 'Dr. Reddy's laboratories: realizing an ambitious vision', IMD case study IMD-3-2117, Lausanne, Switzerland.
18. Chaudhuri, S. (2005) The WTO and India's Pharmaceutical Industry: Patent Protection, TRIPS, and Developing Countries, Oxford University Press, Oxford.
19. Chittoor, R. and Ray, S. (2007) 'Internationalization paths of Indian pharmaceutical firms - a strategic group analysis', Journal of International Management, Vol. 13, pp.338-355.
20. Chittoor, R., Ray, S., Aulakh, P. and Sarkar, M. (2008) 'Strategic responses to institutional changes: 'indigenous growth' model of the Indian pharmaceutical industry', Journal of International Management, Vol. 14, pp.252-269.
21. Chittoor, R., Ray, S., Aulakh, P. and Sarkar, M. (2009) 'Third-world copycats to emerging multinationals: institutional changes and organizational transformation in the Indian pharmaceutical industry', Organization Science, Vol. 20, No. 1, pp.187-205.
22. Clinton, P. and Mozeson, M. (2010) 'Pharm Exec 50', Pharmaceutical Executive, pp.69-80.
23. CMR (Center for Medicines Research) (2010) CMR International 2010 Pharmaceutical R&D Factbook, Thomson Reuters, CRM International, London, UK.
24. Cohen, W.M. and Levinthal, D.A. (1990) 'Absorptive capacity: a new perspective on learning and innovation', Administrative Science Quarterly, Vol. 35, No. 1, pp.128-152.
25. Cygnus (2006) 'White paper on Indian pharma industry - quest for global leadership' Conference Paper for Assocham Conference, 14 November 2006, Cygnus Business Consulting & Research, New Delhi, India.
26. DiMasi, J.A. and Grabowski, H.G. (2007) 'The cost of biopharmaceutical R&D: is biotech different?', Managerial and Decision Economics, Vol. 28, pp.469-479.
27. Dunning, J.H. (1998) 'Location and multinational enterprise: a neglected factor?', Journal of International Business Studies, Vol. 29, No. 1, pp.45-66.
28. EFPIA (2010) 'European federation of pharmaceutical industries and associations', The Pharmaceutical Industry in Figures, Brussels, Belgium.
29. Eisenhardt, K.M. and Graebner, M.E. (2007) 'Theory building from cases: opportunities and challenges', Academy of Management Journal, Vol. 50, No. 1, pp.25-32.
30. Evalueserve (2008) 'Patenting landscape in India', Whitepaper No. 16, Evalueserve, Bangalore, India.
31. FDA (2010) Drugs@FDA - original abbreviated new drug application (ANDA) approvals (by month). Available online at: http://www.accessdata.fda.gov (accessed on 25 August 2010).
32. Fontanella-Khan, J. and Jack. A. (2010) 'Abott buys India drugs unit for $3.7 bn.', Financial Times, London, UK.
33. Gassmann, O. and Reepmeyer, G. (2005) 'Organizing pharmaceutical innovation: from sciencebased knowledge creators to drug-oriented knowledge brokers', Creativity & Innovation Management, Vol. 14, No. 3, pp.233-245. (Pubitemid 41288124)
34. Ghemawat, P. (2010) Strategy and the Business Landscape, Pearson, Upper Saddle River, NJ.
35. GOI (2009) Annual Report, Department of Pharmaceuticals, Government of India, New Delhi.
36. Greene, W. (2007) 'The emergence of India's pharmaceutical industry and implications for the U.S. generic drug market', Office of Economics Working Paper No. 2007-05-A, U.S. International Trade Commission, Washington, DC.
37. Guillén, M.F. and Garcia-Canal, E. (2009) 'The American model of the multinational firm and the 'new' multinationals from emerging economies', Academy of Management Perspectives, Vol. 23, No. 2, pp.23-35.
38. Hill, R. and Chui, M. (2009) 'The pharmerging future', Pharmaceutical Executive, Vol. 29, No. 7, pp.44-52.
39. IMS (2010) IMS forecasts global pharmaceutical market growth of 5-8% annually through 2014; maintains expectations of 4-6% growth in 2010, Available online at: www.imshealth.com (accessed on 20 June 2010).
40. India Knowledge@Wharton (2010) A 'bigger foothold': what does the Abott-Piramal deal mean for Indian pharma? Available online at: http://knowledge.wharton.upenn.edu (accessed on 10 June 2010).
41. Jayakumar, P.B. and Barman, A. (2010) 'Making money was not the reason for this sale', Business Standard, 22 May, New Delhi, India.
42. Kale, D. (2009) 'International migration, knowledge diffusion and innovation capacities in the Indian pharmaceutical industry', New Technology, Work and Employment, Vol. 24, No. 3, pp.260-276.
43. Kale, D. (2010) 'The distinctive patterns of dynamic learning and inter-firm differences in the Indian pharmaceutical industry', British Journal of Management, Vol. 21, pp.223-238.
44. Kale, D. and Little, S. (2007) 'From imitation to innovation: the evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry', Technology Analysis & Strategic Management, Vol. 19, No. 5, pp.589-609. (Pubitemid 47393878)
45. Khanna, T. and Palepu, K. (2006) 'Emerging giants - building world class companies in developing countries', Harvard Business Review, Vol. 84, No. 10, pp.60-70.
46. Kim, L. (1997) From Imitation to Innovation: The Dynamics of Korea's Technological Learning, Harvard Business Press, Boston, MA.
47. Kim, L. and Nelson, R.R. (2000) 'Introduction: technology, and industrialisation in newly industrialising countries', in Kim, L. and Nelson, R.R. (Eds): Technology, Learning and Innovation: Experiences of Newly Industrialising Economies, Cambridge University Press, Cambridge, pp.1-10.
48. Knol (2010) M&A Review: pharmaceutical & biotechnology industry. Available online at: http://knol.google.com (accessed on 27 July 2010).
49. KPMG (2006) The Indian Pharmaceutical Industry - Collaboration for Growth, KPMG International.
50. KPMG (2009) Global M&A: Outlook for Pharmaceuticals, KPMG International.
51. Lee, K. and Lim, C.S. (2001) 'Technological regimes, catching-up and leapfrogging: findings from the Korean industries, Research Policy, Vol. 30, No. 3, pp.459-483. (Pubitemid 33674596)
52. Levin, R.C., Klevorick, A.K., Nelson, R.R. and Winter, S.G. (1987) 'Appropriating the returns from industrial research and development', Brookings Papers on Economic Activity No. 3, Vol. 1987, No. 3, pp.783-831.
53. Manil, S. (2006) 'Sectoral system of innovation of Indian pharmaceutical industry', Working Paper No. 382, Centre for Development Studies, Trivandrum, India.
54. Mathews, J.A. (2002) Dragon Multinationals - A New Model for Global Growth, Oxford University Press, Oxford.
55. Mathews, J.A. (2006) 'Dragon multinationals: new players in 21st century globalization', Asia Pacific Journal of Management, Vol. 23, No. 1, pp.5-27. (Pubitemid 43296501)
56. McKinsey (2007) India pharma 2015 - unlocking the potential of the Indian pharmaceutical market, McKinsey&Company.
57. Motilal Oswal Securities Ltd. (2010) CRAMS - In Calmer Waters, Mumbai, India.
58. Mueller, J.M. (2006) 'The tiger awakens: the tumultuous transformation of India's patent system and the rise of Indian pharmaceutical innovation', University of Pittsburgh School of Law Working Paper Series, Working Paper 43, Pittsburgh, US.
59. Mueller, J.M. (2008) 'Biotechnology patenting in India: will bio-generics lead a 'sunrise industry' to bio-innovation?', Legal Studies Research Paper Series, Working Paper No. 2008-2, School of Law, University of Pittsburgh, US.
60. North, D. (1990) Institutions, Institutional Change and Economic Performance, Cambridge University Press, Cambridge.
61. Peng, M.W., Wang, D.Y. and Yi, J. (2008) 'An institution-based view of international business strategy: a focus on emerging economies', Journal of International Business Studies, Vol. 39, pp.920-936.
62. Pisano, G.P. (1996) The Development Factory: Unlocking the Potential of Process Innovation, Harvard Business School, Mass, Boston.
63. PWC (2010) Global Pharma Looks to India: Prospects for Growth, PriceWaterhouseCoopers.
64. Pradhan, J.P. (2008) Overcoming Innovation Limits Through Outward FDI: The Overseas Acquisition Strategy of Indian Pharmaceutical Firms, Working Paper, Institute for Studies in Industrial Development, New Delhi, India.
65. Ramamurti, R. (2008) 'What have we learned about EMNEs', in Ramamurti, R. and Singh, J. (Eds): Emerging Multinationals from Emerging Markets, Chapter 13, Cambridge University Press, Cambridge.
66. Rothaermel, F.T. (2001) 'Incumbent's advantage through exploiting complementary assets via interfirm cooperation', Strategic Management Journal, Vol. 22, pp.687-699. (Pubitemid 33612464)
67. Sharma, E.K. (2009) 'Indian pharma's search for the magic pill', Business Today, 29 November, Mumbai, India.
68. Sharma, E.K. (2010) 'Beyond betafarm', Business Today, 21 March, Mumbai, India.
69. Sirkin, H.L., Hemerling, J.W. and Bhattacharya, A.K. (2008) Globality - Competing with Everyone from Everywhere for Everything, Boston Consulting Group/Business Plus, New York.
70. Teece, D.J., Pisano, G. and Shuen, A. (1997) 'Dynamic capabilities and strategic management', Strategic Management Journal, Vol. 18, pp.509-533. (Pubitemid 127467809)
71. Wadhwa, V., Rising, B.A., Gereffi, G., Trumpbour, J. and Engardio, P. (2008) The Globalization of Innovation: Pharmaceuticals - Can China and India Cure the Global Pharmaceutical Market?, Ewing Marion Kauffman Foundation, Kansas City, MO.
72. Yadong, L. and Tung, R.L. (2007) 'International expansion of emerging market enterprises: a springboard perspective', Journal of International Business Studies, Vol. 38, pp.481-484.
73. Yee, A. (2008) 'Big pharma meets generics as sons hand over "crown jewel™', Financial Times, 16 June, London, UK.
74. Yin, R.K. (1994) Case Study Research: Design and Methods, 2nd ed., Sage, Newbury Park, CA.